close
or

Closed ATM View - RFT 1718-02

Genomics Cancer Clinical Trials Initiative National Technical Service

Contact Details

Dr Moses Mutie

: 02 6217 9816

:

:
RFT 1718-02
:
Cancer Australia
:
85130000 - Medical science research and experimentation
:
11-Jul-2018 5:00 pm (ACT Local Time)
Show close time for other time zones
:
15-Jun-2018
:
ACT, NSW, VIC, SA, WA, QLD, NT, TAS
Canberra, Sydney, Melbourne, Adelaide, Perth, Brisbane, Darwin, Hobart
:
Request for Tender

:
No
:
No
:
No

:

This procurement seeks to contract a provider for the services of a Genomics Cancer Clinical Trials Initiative (GCCTI) National Technical Service that will assist Multi-site Collaborative Cancer Clinical Trials Groups (CTGs) supported by Cancer Australia through the Support for Cancer Clinical Trials program, to develop cancer clinical trial protocols that specifically target cancer mutations/ molecular markers across a range of tumour types. 
The service provider, as Cancer Australia’s GCCTI National Technical Service, will be required to provide, its technical services from 1 August 2018 – 30 June 2021.  The GCCTI will be required to develop cancer clinical trial protocols that specifically target cancer mutations/ molecular markers across a range of tumour types. A minimum of one cancer clinical trial protocol per annum will be developed in consultation with the CTGs supported by Cancer Australia and other key stakeholders, to the point of completion and submission of a competitive grant application.
In achieving this requirement the technical services provided will include, but are not limited to, the following minimum services:
• Developing an engagement strategy to involve CTGs and other relevant stakeholders in the scoping and development of cancer clinical trial protocols that specifically target cancer mutations/ molecular markers across a range of tumour types;
• Conducting workshops with all CTGs and key stakeholders to identify potential molecular targets for the cancer clinical trial protocols;
• Developing and writing cancer clinical trial protocols that that specifically target cancer mutations/ molecular markers across a range of tumour types (including literature reviews, reviews of international cancer mutation/ molecular marker clinical trial protocols, peer review of protocols, statistical design, sample size calculations);
• Writing grant applications for the funding of the cancer clinical trials developed (including preparation of budgets). Grant applications must remain competitive and responsive to the changing requirements of competitive funders of cancer clinical trials.

:

Tenderers are required to provide a detailed proposal to address the requirement, including the delivery methodology, and highlight any competitive advantage or special or unique features of the proposal.  The proposal should indicate timeframes where relevant for the delivery of services and key performance indicators. The proposal should further identify any critical issues or delivery risks and outline the risk management strategy. Tenderers should further provide evidence of the organisation’s and named personnel’s capability and capacity to deliver on the requirement and include evidence of previous performance against a similar requirement.  Tenderers should also provide details of the availability of the named personnel, their role and their estimated time commitment to achieving the proposal.  Details of any back-up plans for staffing should also be included as part of the risk management strategy.

Tenderers should include a detailed budget for each key milestone of the proposal for each financial year that does not exceed $495,000 GST-exclusive per annum.

Please note:
In providing these services the Genomics Cancer Clinical Trials Initiative National Technical Service will be required to establish collaborative relationships with other National Technical Services funded by Cancer Australia.
Funding will not be provided for the conduct and analysis of cancer clinical trials. It is expected that the conduct of clinical trials will be supported by funding obtained through competitive grant applications or from philanthropic donations.
GCCTI will be required to actively engage all CTGs and relevant stakeholders in the development of cancer clinical trial protocols that specifically target cancer mutations/molecular markers.  Cancer Australia will be engaged in identifying relevant stakeholders.

Tenders may be submitted by a single organisation or a consortium.

A Tender submitted by a consortium will only be considered if:
• A lead agency is identified to enter into the  contractual relationship;
• The Tender clearly specifies the details of all members of the consortium; and
• A single point of contact for the consortium is specified.

:

Mandatory Conditions of Participation
The Customer will exclude from consideration any Response that does not meet the following Mandatory Conditions for Participation:

Conditions of participation
1. For legal and accountability reasons, only incorporated bodies can enter into a Contract with the Australian Government.  It is not necessary for the respondent to become a company limited by guarantee or a separately incorporated body.  The respondent, if not an incorporated body, may nominate an incorporated body to act on its behalf.  The incorporated body will receive funding payments from Cancer Australia and make these available to the respondent.
2. The service provider/incorporated body must have the capacity to comply with the conditions of the draft Contract from a commercial, financial or technical perspective.
3. Have, or be willing to maintain, if engaged the following minimum levels of insurance and indemnity coverage (on a per claim basis) and agree to maintain it for the life of the potential contract:
1. Workers Compensation to an amount required by law;
2. $10,000,000 Public Liability; and
3. $20,000,000 Professional Indemnity.
 

Minimum Content and Format Requirements
1. Quotations must have been approved by signature of an officer authorised to bind the company/organisation;
2. Quotations must be written in English, measurement must be expressed in Australian legal units of measure and any prices quoted must be in Australian dollars;
3. All prices, fees and charges are to include GST (if applicable).

:

1 August 2018 – 30 June 2021

Estimated Value (AUD):
From to $495,000.00
:

AusTender at www.tenders.gov.au, in accordance with instructions in Request documentation

Contact Details

Dr Moses Mutie

: 02 6217 9816

: